| ²é¿´: 777 | »Ø¸´: 4 | ||||
| µ±Ç°Ö÷ÌâÒѾ´æµµ¡£ | ||||
mizunoerͳæ (ÕýʽдÊÖ)
|
[½»Á÷]
¡¾ÇóÖú¡¿¹ØÓÚPEG-PCL
|
|||
| PEG-PCL ×÷ΪÁ½Ç×ÐԸ߷Ö×Ó²ÄÁÏ£¬¿ÉÒÔ×ö³É½ºÊø ²¢³ÉΪҩÎï¿ØÊÍÔØÌå²ÄÁÏ£¬ÏÖÔÚ¿´µ½Ò»Ð©ÎÄÏ×ÉÏ˵PCLÓÉÓڽᾧÐԸߣ¬²»ÀûÓÚÒ©Îï¿ØÊÍ£¬ÎÒ¾ÍÏëÎÊÏ£¬½á¾§ÐÔÇ¿ÊÇÈçºÎÓ°ÏìÒ©Îï¿ØÊ͵ģ¡£¡£¡£¡ |
» ÊÕ¼±¾ÌûµÄÌÔÌûר¼ÍƼö
Ò©Îï¿ØÊÍ |
» ²ÂÄãϲ»¶
°ßÂíÓã·õ»¯ÇóÖú
ÒѾÓÐ0È˻ظ´
Ͷ¸åElsevierµÄNeoplasiaÔÓÖ¾£¬µ½×îºóÑ¡publishing optionsÊ±Ò³Ãæ¿Õ°×£¬²»ÄÜÍê³ÉͶ¸å
ÒѾÓÐ23È˻ظ´
ÉúÎïÁ¦Ñ§Óë×éÖ¯¹¤³ÌѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ210È˻ظ´
ÉúÎïѧ-΢ÉúÎïѧ-²©Ê¿ÉêÇ룬ÓзÖ×ÓÉúÎïѧ¡¢·¢½Í¹¤³Ì¡¢ÉúÎïÐÅϢѧµÈ»ù´¡
ÒѾÓÐ1È˻ظ´
ϤÄá´óѧ AMME »úе¹¤³Ì Ë«ARC Future FellowsÍŶÓÕÐÊÕCSC²©Ê¿Éú
ÒѾÓÐ30È˻ظ´
2026 ·¨¹úcsc ¸öÈËÇþµÀÕÐÆ¸¡£¼ÆËã»ú/ÉúÎïÐÅÏ¢/evolution/networkÓÅÏÈ
ÒѾÓÐ0È˻ظ´
µ°°×Ìõ´øÍá
ÒѾÓÐ1È˻ظ´
½ðÊôÀë×ÓÓ뻯ºÏÎï·Ö×Ó¶Ô½Ó
ÒѾÓÐ1È˻ظ´
ÇóÖú²ÎÜß°×Êõ¿Ú·þÒº¡¢·Ê¶ù¿Ú·þÒº£¬¶ù¿µÄþÌǽ¬µÄÖÊÁ¿±ê×¼£¡
ÒѾÓÐ2È˻ظ´
Ïã¸ÛÖÐÎÄ´óѧҽѧԺ ³ÏƸ Ñо¿ÖúÀí½ÌÊÚ (Ò½¹¤½áºÏ/ÉúÎïÐÅϢѧ·½Ïò)
ÒѾÓÐ21È˻ظ´
» ±¾Ö÷ÌâÏà¹ØÉ̼ÒÍÆ¼ö: (ÎÒÒ²ÒªÔÚÕâÀïÍÆ¹ã)
aegeansyang
Òø³æ (ÕýʽдÊÖ)
- Ó¦Öú: 12 (СѧÉú)
- ½ð±Ò: 5517.1
- É¢½ð: 1825
- ºì»¨: 5
- Ìû×Ó: 856
- ÔÚÏß: 724.4Сʱ
- ³æºÅ: 243919
- ×¢²á: 2006-04-16
- ÐÔ±ð: GG
- רҵ: ×éÖ¯¹¤³Ìѧ
2Â¥2010-02-23 11:03:03
kong0908
ͳæ (ÖøÃûдÊÖ)
Jesus Walks With Me!
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ¹ó±ö: 0.47
- ½ð±Ò: 196.8
- É¢½ð: 452
- ºì»¨: 6
- Ìû×Ó: 2507
- ÔÚÏß: 75.2Сʱ
- ³æºÅ: 610751
- ×¢²á: 2008-09-23
- ÐÔ±ð: GG
- רҵ: ¹¦ÄÜÓëÖÇÄܸ߷Ö×Ó

3Â¥2010-02-23 19:05:21
kong0908
ͳæ (ÖøÃûдÊÖ)
Jesus Walks With Me!
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ¹ó±ö: 0.47
- ½ð±Ò: 196.8
- É¢½ð: 452
- ºì»¨: 6
- Ìû×Ó: 2507
- ÔÚÏß: 75.2Сʱ
- ³æºÅ: 610751
- ×¢²á: 2008-09-23
- ÐÔ±ð: GG
- רҵ: ¹¦ÄÜÓëÖÇÄܸ߷Ö×Ó
¡ï ¡ï ¡ï
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû½»Á÷
Þ¹Ò²ݶù(½ð±Ò+2):»¶Ó½»Á÷~ 2010-03-01 10:57
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû½»Á÷
Þ¹Ò²ݶù(½ð±Ò+2):»¶Ó½»Á÷~ 2010-03-01 10:57
|
ÎÒÕÒµ½ÁËЩÐÅÏ¢£¬ÎҾͲ»·ÒëÁ˰¡£¬Ò»ÆðѧϰÁË¡£ ¡°.....In addition to the hydrophobic interactions between PCL and DOX, two other factors, i.e. the PCL crystallinity and hydrogen-bonding interactions between DOX and PCL, are hypothesized to affect the DLC. Higher PCL crystallinity in the micelle cores will decrease the DLC because only the amorphous PCL phase is likely to accommodate drug molecules. For semi-crystalline polymers such as PCL, higher molecular weight usually leads to higher crystallinity. Although the micelle cores constructed with longer PCL segments are generally bigger in size and may encapsulate more drug molecules, the higher PCL crystallinity may lead to less DOX-loading in the micelles. Meanwhile, the deprotonated DOX contains hydroxyl and amino groups, which may form hydrogen-bonds with the carbonyl groups of the amorphous PCL. For shorter PCL segments that have lower crystallinity, the H-bonding interactions can enhance the DOX-loading in the micelle cores.¡± J. of controlled release 98 (2004) 415-426 |

4Â¥2010-02-23 19:11:58
mizunoer
ͳæ (ÕýʽдÊÖ)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 72.9
- É¢½ð: 387
- ºì»¨: 1
- Ìû×Ó: 850
- ÔÚÏß: 77.4Сʱ
- ³æºÅ: 257850
- ×¢²á: 2006-06-04
- ÐÔ±ð: GG
- רҵ: ¹¦ÄÜÓëÖÇÄܸ߷Ö×Ó
5Â¥2010-02-27 19:54:13













»Ø¸´´ËÂ¥

